Xeris Biopharma Holdings, Inc. (FRA:2B30)
Germany · Delayed Price · Currency is EUR | Market Cap | 901.96M +28.6% |
| Revenue (ttm) | 273.07M +41.5% |
| Net Income | 10.41M |
| EPS | 0.06 |
| Shares Out | n/a |
| PE Ratio | 86.61 |
| Forward PE | 38.50 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 5.12 |
| Previous Close | 5.20 |
| Day's Range | 5.12 - 5.12 |
| 52-Week Range | 3.72 - 8.48 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 7, 2026 |
About Xeris Biopharma Holdings
Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patient... [Read more]
News
Xeris Biopharma Holdings Earnings Call Transcript: Q1 2026
Q1 2026 saw 43% net product revenue growth, led by RECORLEV's 95% surge and strong KEVEYIS performance, while GVOKE was flat due to Medicare headwinds. Full-year revenue guidance was raised, and commercial expansion is expected to drive further growth.
Xeris Biopharma Holdings Earnings release: Q1 2026
Xeris Biopharma Holdings released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Xeris Biopharma Holdings Quarterly report: Q1 2026
Xeris Biopharma Holdings has published its Q1 2026 quarterly earnings report on May 7, 2026.
Xeris Biopharma Reports First Quarter 2026 Financial Results
CHICAGO--(BUSINESS WIRE)--XERIS BIOPHARMA REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS.
Xeris Biopharma Holdings Proxy statement: Proxy filing
Xeris Biopharma Holdings filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Xeris Biopharma Holdings Proxy statement: Proxy filing
Xeris Biopharma Holdings filed a proxy statement on April 23, 2026, providing details for shareholder voting and corporate governance matters.
Xeris Biopharma to Report First Quarter 2026 Financial Results on May 7, 2026
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
Xeris Biopharma Holdings Transcript: Barclays 28th Annual Global Healthcare Conference
Revenue grew 44% to $292 million in 2025, with RECORLEV driving growth and a strong pipeline led by XP-8121 entering phase III. Investments in commercial expansion and R&D are expected to sustain momentum, while robust IP and a strengthened balance sheet support long-term targets.
Xeris Biopharma Holdings Slides: Corporate presentation
Xeris Biopharma Holdings has posted slides in relation to its latest quarterly earnings report, which was published on March 4, 2026.
Xeris Biopharma Holdings Earnings Call Transcript: Q4 2025
Achieved record revenue and first full-year net income in 2025, driven by strong growth across all products and disciplined execution. 2026 guidance projects over 30% revenue growth, with major investments in pipeline and commercial expansion, while maintaining positive Adjusted EBITDA.
Xeris Biopharma Holdings Annual report: Q4 2025
Xeris Biopharma Holdings has published its Q4 2025 annual report on March 2, 2026.
Xeris Biopharma Holdings Earnings release: Q4 2025
Xeris Biopharma Holdings released its Q4 2025 earnings on March 2, 2026, summarizing the period's financial results.
Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
Xeris Biopharma subsidiaries file Recorlev patent infringement lawsuit
Xeris Biopharma’s (XERS) subsidiaries Xeris Pharmaceuticals and Strongbridge Dublin have filed a patent infringement lawsuit under the Hatch-Waxman Act related to Recorlev in the U.S. District Court f...
Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS) today announced unaudited preliminary financial results for the fourth quarter and fiscal year 2025, and other highlights. "Our ...
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
Xeris Biopharma initiated with an Overweight at Barclays
Barclays initiated coverage of Xeris Biopharma (XERS) with an Overweight rating and $9 price target The firm rolled out coverage on the specialty pharmaceuticals industry with a neutral view, saying…
Xeris Biopharma Holdings Transcript: Piper Sandler 37th Annual Healthcare Conference
Significant revenue growth and profitability have enabled reinvestment in commercial expansion, especially for Recorlev, which is positioned as a key growth driver with robust IP protection. Gvoke and Keveyis maintain stable performance, while pipeline asset XP-8121 targets a large unmet need. Commercial infrastructure is highly leverageable for future launches.
Xeris Biopharma issued notice of allowance from USPTO for XP-8121
Xeris Biopharma (XERS) announced that the United States Patent and Trademark Office has issued a notice of allowance for its subsidiary Xeris Pharmaceuticals’ U.S. patent application covering XP-8121,...
Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative prod...
Xeris Biopharma price target raised to $8 from $6 at Piper Sandler
Piper Sandler analyst David Amsellem raised the firm’s price target on Xeris Biopharma (XERS) to $8 from $6 and keeps a Neutral rating on the shares. The firm notes Xeris…
Xeris Biopharma Holdings Earnings Call Transcript: Q3 2025
Q3 saw record revenue growth of 40% year-over-year, with Recorlev leading at 109% growth and the company achieving its first-ever net income. Full-year guidance was raised, and major commercial expansion and pipeline progress position the business for continued strong growth.